This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
FIRE-4.5 is a randomized phase 2 clinical trial evaluating two first-line treatment strategies in patients with BRAF-mutated metastatic colorectal cancer. The study compares FOLFOXIRI plus cetuximab with FOLFOXIRI plus bevacizumab using a parallel-group design.
| Feature | FIRE-4.5 |
|---|---|
| NCT ID | NCT04034459 |
| Condition | Metastatic Colorectal Cancer |
| Phase | Phase 2 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Single |
| Primary purpose | Treatment |
| Lead sponsor | Ludwig-Maximilians - University of Munich |
| Study dates | Start date: 2016-11-25; Primary completion date: 2023-11-01 |
2. Clinical Question
The central question of FIRE-4.5 is whether two different combinations of FOLFOXIRI-based first-line therapy produce different tumor response outcomes in patients with BRAF-mutated metastatic colorectal cancer.
Population
Patients with metastatic colorectal cancer and BRAF mutation status as defined by the trial population.
Intervention
FOLFOXIRI plus cetuximab.
Comparator
FOLFOXIRI plus bevacizumab.
Primary question
Does one treatment strategy demonstrate a different overall response rate measured according to RECIST 1.1 criteria?
3. Trial Design
Randomized
Parallel assignment
Single masking
Treatment
| Arm | Interventions |
|---|---|
| FOLFOXIRI plus cetuximab | Cetuximab, irinotecan, folinic acid, oxaliplatin, and 5-FU |
| FOLFOXIRI plus bevacizumab | Bevacizumab, irinotecan, folinic acid, oxaliplatin, and 5-FU |
4. Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Overall Response Rate (ORR) | Overall response rate measured in percentage of all treated patients according to RECIST 1.1 criteria | Up to 48 months |
5. Planned Analysis
The ClinicalTrials.gov record identifies Overall Response Rate (ORR) as the primary endpoint. ORR is a binary tumor-response outcome, generally summarized as the proportion of treated patients who achieve a prespecified response category according to the assessment criteria.
For randomized oncology trials, response rates are commonly compared between treatment groups using methods appropriate for proportions, with confidence intervals used to describe uncertainty around estimated response differences or ratios.
No formal statistical analyses were posted to ClinicalTrials.gov for the primary endpoint.
6. Statistical Methodology
Overall Response Rate
Overall Response Rate summarizes the fraction of patients whose tumors meet predefined response criteria. Unlike time-to-event endpoints such as progression-free survival or overall survival, ORR focuses on whether a response occurred rather than the duration until an event.
A higher response proportion indicates that more patients achieved the defined tumor response category. The estimate does not describe response durability, survival, or all clinical outcomes.
RECIST 1.1 Assessment
The primary endpoint is defined using RECIST 1.1 criteria. RECIST-based response assessment provides standardized rules for categorizing tumor response across clinical trials.
Randomized Treatment Comparison
Randomization is intended to balance known and unknown patient characteristics between treatment groups. In a randomized comparison, differences in outcomes can be interpreted in relation to the assigned treatment strategies, while recognizing the uncertainty of statistical estimates.
7. Statistical Methods Explained
Why use ORR as the primary endpoint?
ORR directly measures tumor response activity and is often used in oncology trials when treatment effects on tumor shrinkage are an important study objective.
What does RECIST 1.1 contribute?
RECIST 1.1 provides standardized response categories, allowing response assessments to be compared consistently across patients and treatment groups.
Why does randomization matter?
Randomization reduces systematic differences between treatment groups, supporting a more reliable comparison of outcomes.
Why are confidence intervals important?
Confidence intervals describe uncertainty around an estimated treatment effect and indicate how precisely the observed result has been estimated.
Why is ORR different from survival?
A response endpoint measures tumor shrinkage, while survival endpoints measure time until clinical events. They answer different statistical questions.
Why does analysis timing matter?
Endpoints assessed over longer follow-up can include additional patient information and may provide a different statistical perspective than earlier assessments.
8. Limitations
- No posted efficacy estimates: The registry does not report numerical ORR results, confidence intervals, or p-values.
- Limited endpoint information: The posted registry record identifies the primary endpoint but does not provide secondary endpoint analyses.
- Study phase: As a phase 2 randomized trial, the study design focuses on evaluating treatment activity rather than providing the scale of evidence typically associated with large confirmatory trials.
- Generalizability: The population is limited to patients represented by the trial eligibility criteria and the specific BRAF-mutated metastatic colorectal cancer setting.
9. Why This Trial Matters Statistically
FIRE-4.5 provides an example of how randomized oncology trials compare active treatment strategies using response-based endpoints. The trial illustrates several important statistical principles.
| Concept | How it appears in FIRE-4.5 |
|---|---|
| Randomization | Patients are assigned using a randomized parallel-group design. |
| Comparative effectiveness | Two FOLFOXIRI-based treatment strategies are compared. |
| Binary endpoint analysis | ORR evaluates whether patients achieve RECIST 1.1-defined response. |
| Uncertainty estimation | Confidence intervals are used to quantify precision around treatment-effect estimates. |
| Oncology response assessment | RECIST 1.1 provides standardized tumor-response categories. |
10. Related Clinical Trial Results
11. Sources
- ClinicalTrials.gov: NCT04034459.
Continue through the Clinical Biostats trial library
Explore additional clinical trial analyses, statistical tutorials, and calculator-based workflows.
12. Record Summary
FIRE-4.5 is a randomized phase 2 trial evaluating FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab in BRAF-mutated metastatic colorectal cancer. The registry identifies Overall Response Rate according to RECIST 1.1 criteria as the primary endpoint with assessment up to 48 months. The statistical framework centers on randomized treatment comparison, standardized response assessment, and interpretation of uncertainty around treatment-effect estimates.